Other News To Note
Tuesday, November 29, 2011
Galena Biopharma Inc., of Lake Oswego, Ore., entered a clinical development collaboration with Genentech Inc., of South San Francisco, and the Henry M. Jackson Foundation for the Advancement of Military Medicine to develop NeuVax (E75) in combination with Genentech's Herceptin (trastuzumab) in adjuvant breast cancer patients currently not eligible for Herceptin therapy. Genentech and Galena will sponsor a randomized, blinded multicenter Phase II study in adjuvant breast cancer in about 300 subjects.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.